MetaCap

Illumina (ILMN) vs Natera (NTRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Illumina (ILMN) has outperformed Natera (NTRA) over the past year, gaining 55.7% versus a gain of 18.5%. Over five years, NTRA leads with a +188.8% price change compared with -46.4% for ILMN. Natera is the larger company by market cap ($39.64 billion vs $29.15 billion), about 1.4 times the size.

Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -9.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ILMN+55.69%NTRA+18.54%
+145%+58%-29%
Nov 21, 20251 yearNov 20, 2026
ILMN-47.75%NTRA+164.97%
+321%+110%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ILMN versus NTRA key metrics
MetricILMNNTRA
Share price$192.82$273.40
Market cap$29.15B$39.64B
1-day change-3.90%-5.70%
YTD return+47.01%+19.34%
1-year return+55.69%+18.54%
5-year return-46.40%+188.82%
P/E ratio (TTM)33.19—
Forward P/E31.19—
EPS (TTM)$5.81$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.34B$2.31B
Revenue growth (YoY)-0.66%+35.90%
Net income (latest FY)$850.00M$-208.16M
Gross margin66.08%—
Operating margin18.58%-13.44%
Net margin19.57%-9.03%
52-week high$309.35$437.41
52-week low$112.65$181.00
Distance from 52-week high-37.67%-37.50%
Analyst consensusbuystrong_buy
Avg. price target upside+35.59%+50.06%
Average volume2.82M1.77M
Shares outstanding151.20M145.00M
Employees8,6006,135
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ILMN has outperformed NTRA by 37.1 percentage points over the past year.
  • Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -9.0 cents for Natera.
  • Natera grew revenue faster in its latest fiscal year (+35.90% vs -0.66%).

About Illumina

ILMN stock →

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Health Care · Medical Specialities · 8,600 employees

About Natera

NTRA stock →

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.

Health Care · Medical Specialities · 6,135 employees

ILMN vs NTRA FAQ

Which is bigger, Illumina or Natera?

Natera (NTRA) is larger, with a market capitalization of $39.64B compared with $29.15B for Illumina (ILMN).

Which stock has performed better over the past year, ILMN or NTRA?

ILMN returned +55.69% over the past 12 months, compared with +18.54% for NTRA (price return, excluding dividends). Past performance does not predict future results.

Are Illumina and Natera in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons